The World Health Organization has approved a second cervical cancer vaccine, Cervarix. Like the quadrivalent human papillomavirus (HPV) vaccine Gardasil, Cervarix targets HPV types 16 and 18 (the cause of 70% of cervical cancer) and, according to the results of a study in the July 7 Lancet, also blocks HPV types 31, 33, and 45. Cervarix is approved in 97 countries. GlaxoSmithKline, the manufacturer of Cervarix, has donated 100,000 doses to immunization programs aimed at protecting women in poor countries. U.S. approval is pending.